Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), announced the United States Patent and Trademark Office has issued a patent to the Company which covers its drug candidate, CF102, in the treatment of liver regeneration and function following liver surgery. The issued patent # 8,846,635 is titled, “Method for inducing hepatocyte proliferation and uses thereof.” Can-Fite has recently been granted a patent for this technology in Japan and the European Union. CF102 is now entering Phase II trials for the treatment of hepatocellular carcinoma, the most common form of liver cancer in the U.S., Europe and Israel. The U.S. Food and Drug Administration has granted Orphan Drug Status to Can-Fite’s CF102 for this indication and Israel’s Ministry of Health has approved CF102 for Compassionate Use in liver cancer. In preclinical studies, CF102 has induced proliferation of hepatocytes following liver resection (surgery), increased liver weight and reduced elevated levels of serum liver enzymes, reflecting improved liver status. In patients with preexisting liver diseases, such as cirrhosis or cancer, normal hepatocellular proliferation following injury is impaired, exposing patients to liver dysfunction and associated complications that can lead to liver failure and death.